Market revenue in 2023 | USD 485.0 million |
Market revenue in 2030 | USD 798.2 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 91.79% in 2023. Horizon Databook has segmented the Germany hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for leading revenue share in European market, owing to substantial number of key players operating in this region and their efforts to reinforce market presence. Some of the major players engaged in offering hereditary testing solutions are Centogene N.V., LifeCodexx AG, CeGaT GmbH, and Eluthia.
For instance, in June 2019, BGI Genomics and Eluthia introduced an NIPT called NIFTY test, in Germany. The test was launched under the brand name PreviaTest. This product launch enabled patient access to comprehensive NIPT solutions in Germany. Furthermore, key vendors are collaborating with other companies to leverage core competencies and strengthen their market position.
For instance, in March 2016, LifeCodexx AG partnered with several leading laboratory groups in Germany and Switzerland to expand its NIPT technology access to include new partners. This significantly enhanced access to PrenaTest, Europe's first NIPT, for gynecologists via a strong medical customer and support network, provided by the partner laboratories.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Germany hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account